KR102634732B1 - 마크로시클릭 화합물 및 그의 용도 - Google Patents

마크로시클릭 화합물 및 그의 용도 Download PDF

Info

Publication number
KR102634732B1
KR102634732B1 KR1020197032300A KR20197032300A KR102634732B1 KR 102634732 B1 KR102634732 B1 KR 102634732B1 KR 1020197032300 A KR1020197032300 A KR 1020197032300A KR 20197032300 A KR20197032300 A KR 20197032300A KR 102634732 B1 KR102634732 B1 KR 102634732B1
Authority
KR
South Korea
Prior art keywords
cancer
pharmaceutical composition
tumor
compound
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197032300A
Other languages
English (en)
Korean (ko)
Other versions
KR20190137121A (ko
Inventor
요시토 키시
가즈노부 키라
켄 이토
Original Assignee
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/814,105 external-priority patent/US9938288B1/en
Application filed by 프레지던트 앤드 펠로우즈 오브 하바드 칼리지, 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Priority to KR1020247003838A priority Critical patent/KR102836514B1/ko
Publication of KR20190137121A publication Critical patent/KR20190137121A/ko
Application granted granted Critical
Publication of KR102634732B1 publication Critical patent/KR102634732B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197032300A 2017-04-05 2018-04-03 마크로시클릭 화합물 및 그의 용도 Active KR102634732B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247003838A KR102836514B1 (ko) 2017-04-05 2018-04-03 마크로시클릭 화합물 및 그의 용도

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762482030P 2017-04-05 2017-04-05
US62/482,030 2017-04-05
US201762526677P 2017-06-29 2017-06-29
US62/526,677 2017-06-29
US201762586416P 2017-11-15 2017-11-15
US15/814,105 2017-11-15
US62/586,416 2017-11-15
US15/814,105 US9938288B1 (en) 2017-04-05 2017-11-15 Macrocyclic compound and uses thereof
PCT/US2018/025887 WO2018187331A1 (en) 2017-04-05 2018-04-03 Macrocyclic compound and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003838A Division KR102836514B1 (ko) 2017-04-05 2018-04-03 마크로시클릭 화합물 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20190137121A KR20190137121A (ko) 2019-12-10
KR102634732B1 true KR102634732B1 (ko) 2024-02-13

Family

ID=63104288

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197032300A Active KR102634732B1 (ko) 2017-04-05 2018-04-03 마크로시클릭 화합물 및 그의 용도
KR1020247003838A Active KR102836514B1 (ko) 2017-04-05 2018-04-03 마크로시클릭 화합물 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247003838A Active KR102836514B1 (ko) 2017-04-05 2018-04-03 마크로시클릭 화합물 및 그의 용도

Country Status (33)

Country Link
US (2) US11725015B2 (enExample)
EP (2) EP4119563A3 (enExample)
JP (4) JP7168580B2 (enExample)
KR (2) KR102634732B1 (enExample)
CN (2) CN115093429B (enExample)
AU (2) AU2018250147B2 (enExample)
CA (1) CA3056945A1 (enExample)
CL (1) CL2019002854A1 (enExample)
CO (1) CO2019011538A2 (enExample)
DK (1) DK3606928T3 (enExample)
EC (1) ECSP19075677A (enExample)
ES (1) ES2931533T3 (enExample)
HR (1) HRP20221385T1 (enExample)
HU (1) HUE060466T2 (enExample)
IL (2) IL288991B2 (enExample)
JO (1) JOP20190234B1 (enExample)
LT (1) LT3606928T (enExample)
MA (1) MA48027B1 (enExample)
MD (1) MD3606928T2 (enExample)
MX (1) MX389899B (enExample)
PE (1) PE20200602A1 (enExample)
PH (1) PH12019502197A1 (enExample)
PL (1) PL3606928T3 (enExample)
PT (1) PT3606928T (enExample)
RS (1) RS63755B1 (enExample)
SA (1) SA519410259B1 (enExample)
SG (1) SG11201908603PA (enExample)
SI (1) SI3606928T1 (enExample)
SM (1) SMT202200455T1 (enExample)
TW (3) TWI836643B (enExample)
UA (1) UA124399C2 (enExample)
WO (1) WO2018187331A1 (enExample)
ZA (1) ZA201906279B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3160970A4 (en) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
JP7168580B2 (ja) 2017-04-05 2022-11-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状化合物およびその使用
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
WO2019099646A1 (en) * 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
DE4229425A1 (de) 1992-09-03 1994-03-10 Kodak Ag Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US5352804A (en) * 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
JP2818381B2 (ja) 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
DK1087960T3 (da) 1998-06-17 2011-06-14 Eisai R&D Man Co Ltd Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP2001305734A (ja) 2000-04-20 2001-11-02 Fuji Photo Film Co Ltd 光重合性組成物
JP2003261447A (ja) 2002-03-07 2003-09-16 Kyosei Seiyaku Kk 抗腫瘍剤
HUE046436T2 (hu) 2004-06-03 2020-02-28 Eisai R&D Man Co Ltd Köztitermékek halikondrin B elõállításához
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
JP2008522623A (ja) 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TWI551098B (zh) 2007-03-07 2016-09-21 內數位科技公司 產生及處理ＭＡＣ－ｅｈｓ協定資料單元方法及裝置
JP2010530437A (ja) 2007-06-18 2010-09-09 メディミューン，エルエルシー ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療
US8093410B2 (en) 2007-10-03 2012-01-10 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin B analogs
WO2009064029A1 (en) 2007-11-16 2009-05-22 Eisai R & D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
CA2720632C (en) 2008-04-04 2016-12-20 Eisai R&D Management Co., Ltd. Halichondrin b analogs
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
EP2663337A4 (en) 2011-01-10 2014-06-11 Harvard College METHOD OF DELIVERING AGENTS IN CELLS BY BACTERIAL TOXINE
WO2012147900A1 (en) * 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
CN104024237B (zh) 2011-12-16 2016-02-24 阿方拉研究股份有限公司 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体
CN104080793B (zh) 2011-12-29 2017-09-19 阿方拉研究股份有限公司 2‑((2s,3s,4r,5r)‑5‑((s)‑3‑氨基‑2‑羟基丙‑1‑基)‑4‑甲氧基‑3‑(苯磺酰甲基)四氢呋喃‑2‑基)乙醛衍生物以及它们的制备方法
US9278979B2 (en) 2012-03-30 2016-03-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein
AU2012395673A1 (en) * 2012-11-30 2014-08-14 Hangzhou Zylox Pharma Co., Ltd. Rapamycin analogs and methods for making same
EP2997017B1 (en) 2013-05-15 2017-08-09 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
SG10201805024YA (en) 2013-12-06 2018-07-30 Eisai R&D Man Co Ltd Methods useful in the synthesis of halichondrin b analogs
EP3160970A4 (en) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
EP3191479B1 (en) 2014-09-09 2020-04-08 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
RU2020141025A (ru) 2015-05-07 2020-12-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, полезные в синтезе макролидов галихондринов
JP6795525B2 (ja) * 2015-07-01 2020-12-02 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 炭酸脱水酵素阻害剤としてのアリールスルホンアミド化合物およびその治療的使用
PE20181953A1 (es) 2016-03-02 2018-12-17 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
BR112019017047A2 (pt) 2017-02-20 2020-04-28 Polyphor Ag combinações farmacêuticas para tratar câncer
JP7168580B2 (ja) 2017-04-05 2022-11-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状化合物およびその使用
US9938288B1 (en) * 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US20230135188A1 (en) 2017-07-06 2023-05-04 President And Fellows Of Harvard College Fe/cu-mediated ketone synthesis
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
WO2019009956A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College SUMMARY OF MEDIUM MEDIATED KETONE
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
WO2019099646A1 (en) * 2017-11-15 2019-05-23 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US20230357286A1 (en) 2020-07-24 2023-11-09 President And Fellows Of Harvard College Ketone synthesis and applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Francis G. Fang 등, Tetrahedron letters, 제33권, 페이지 1557-1560

Also Published As

Publication number Publication date
IL288991B1 (en) 2023-08-01
AU2022291454A1 (en) 2023-02-16
AU2018250147B2 (en) 2022-09-29
SG11201908603PA (en) 2019-10-30
PE20200602A1 (es) 2020-03-10
KR102836514B1 (ko) 2025-07-22
JP6366873B1 (ja) 2018-08-08
PH12019502197A1 (en) 2020-12-07
CN115093429A (zh) 2022-09-23
RS63755B1 (sr) 2022-12-30
CO2019011538A2 (es) 2020-02-28
IL288991B2 (en) 2023-12-01
PT3606928T (pt) 2022-12-05
MX389899B (es) 2025-03-20
JOP20190234B1 (ar) 2023-09-17
IL288991A (en) 2022-02-01
ES2931533T3 (es) 2022-12-30
UA124399C2 (uk) 2021-09-08
TW201902902A (zh) 2019-01-16
KR20240023674A (ko) 2024-02-22
MX2019011982A (es) 2019-11-08
CN110831946A (zh) 2020-02-21
RU2019135531A3 (enExample) 2021-09-07
AU2022291454B2 (en) 2024-03-28
JP2018177774A (ja) 2018-11-15
US11725015B2 (en) 2023-08-15
EP3606928A1 (en) 2020-02-12
US20210261566A1 (en) 2021-08-26
CL2019002854A1 (es) 2019-12-27
TW202426457A (zh) 2024-07-01
JP2020513021A (ja) 2020-04-30
IL269788A (en) 2019-11-28
RU2019135531A (ru) 2021-05-05
SI3606928T1 (sl) 2023-02-28
SA519410259B1 (ar) 2022-09-11
PL3606928T3 (pl) 2023-02-06
CA3056945A1 (en) 2018-10-11
MA48027B1 (fr) 2022-12-30
JP2024028872A (ja) 2024-03-05
CN110831946B (zh) 2022-06-21
WO2018187331A1 (en) 2018-10-11
JOP20190234A1 (ar) 2019-10-03
EP4119563A3 (en) 2023-04-05
WO2018187331A8 (en) 2018-12-06
KR20190137121A (ko) 2019-12-10
JP7696416B2 (ja) 2025-06-20
HUE060466T2 (hu) 2023-03-28
EP3606928B1 (en) 2022-09-07
TWI863657B (zh) 2024-11-21
JP2022153392A (ja) 2022-10-12
JP7168580B2 (ja) 2022-11-09
EP4119563A2 (en) 2023-01-18
ZA201906279B (en) 2021-01-27
ECSP19075677A (es) 2020-01-31
LT3606928T (lt) 2022-12-12
SMT202200455T1 (it) 2023-01-13
HRP20221385T1 (hr) 2023-01-06
IL269788B (en) 2022-01-01
AU2018250147A1 (en) 2019-10-03
CN115093429B (zh) 2024-08-30
BR112019020208A2 (pt) 2020-04-22
TWI836643B (zh) 2024-03-21
US12421248B2 (en) 2025-09-23
JP7400025B2 (ja) 2023-12-18
DK3606928T3 (da) 2022-11-28
MD3606928T2 (ro) 2022-12-31
TW202321259A (zh) 2023-06-01
TWI781163B (zh) 2022-10-21
US20230406863A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
US10954249B2 (en) Macrocyclic compound and uses thereof
JP7696416B2 (ja) 大環状化合物およびその使用
CN111566113A (zh) 大环化合物及其用途
RU2783238C2 (ru) Макроциклическое соединение и его применения
EA040298B1 (ru) Макроциклическое соединение и его применения для ингибирования роста опухоли или рака
HK40025968B (en) Macrocyclic compound and uses thereof
HK40025968A (en) Macrocyclic compound and uses thereof
BR112019020208B1 (pt) Composto macrocíclico, composição farmacêutica e uso dos mesmos

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601